Form D · Biotechnology
ImmuneID, Inc.
Boston, MA · CIK 0001840105
Offering snapshot reported Jan 13, 2021 · SEC filing
- Reported sold
- $17.1M Offering amount: $20.2M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 29, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 13, 2021 | Initial | $17,100,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-386228
Source: Form D, filed Jan 13, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lea Hachigian | Director, Executive |
| Ittai Harel | Director |
| Christoph Westphal | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
800 Boylston Street Suite 1555
Boston, MA, 02199
Boston, MA, 02199